WO2000064946A3 - Compositions and methods for cancer treatment by selectively inhibiting vegf - Google Patents

Compositions and methods for cancer treatment by selectively inhibiting vegf Download PDF

Info

Publication number
WO2000064946A3
WO2000064946A3 PCT/US2000/011367 US0011367W WO0064946A3 WO 2000064946 A3 WO2000064946 A3 WO 2000064946A3 US 0011367 W US0011367 W US 0011367W WO 0064946 A3 WO0064946 A3 WO 0064946A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
vegf
cancer treatment
antibodies
Prior art date
Application number
PCT/US2000/011367
Other languages
French (fr)
Other versions
WO2000064946A2 (en
Inventor
Philip E Thorpe
Rolf A Brekken
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22449437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000064946(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2000614295A priority Critical patent/JP4926320B2/en
Priority to IL145941A priority patent/IL145941A/en
Priority to BR0010017-0A priority patent/BR0010017A/en
Priority to MXPA01010891A priority patent/MXPA01010891A/en
Priority to KR1020017013746A priority patent/KR100816572B1/en
Application filed by Univ Texas filed Critical Univ Texas
Priority to NZ514918A priority patent/NZ514918A/en
Priority to CA002372053A priority patent/CA2372053C/en
Priority to EP00930183A priority patent/EP1185559A2/en
Priority to AU48049/00A priority patent/AU763954B2/en
Publication of WO2000064946A2 publication Critical patent/WO2000064946A2/en
Publication of WO2000064946A3 publication Critical patent/WO2000064946A3/en
Priority to HK02106774.7A priority patent/HK1045700B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Abstract

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
PCT/US2000/011367 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf WO2000064946A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU48049/00A AU763954B2 (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting VEGF
IL145941A IL145941A (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf
BR0010017-0A BR0010017A (en) 1999-04-28 2000-04-28 Compositions and processes for the treatment of cancer by selective vegf inhibition
MXPA01010891A MXPA01010891A (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf.
KR1020017013746A KR100816572B1 (en) 1999-04-28 2000-04-28 Anti-VEGF antibody and a pharmaceutical composition comprising the same
JP2000614295A JP4926320B2 (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selective inhibition of VEGF
NZ514918A NZ514918A (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting VEGF
CA002372053A CA2372053C (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf
EP00930183A EP1185559A2 (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf
HK02106774.7A HK1045700B (en) 1999-04-28 2002-09-16 Compositions an methods for cancer treatment by selectively inhibiting vegf

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13143299P 1999-04-28 1999-04-28
US60/131,432 1999-04-28

Publications (2)

Publication Number Publication Date
WO2000064946A2 WO2000064946A2 (en) 2000-11-02
WO2000064946A3 true WO2000064946A3 (en) 2001-02-15

Family

ID=22449437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011367 WO2000064946A2 (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf

Country Status (17)

Country Link
US (7) US6524583B1 (en)
EP (2) EP1179541B1 (en)
JP (2) JP4926320B2 (en)
KR (1) KR100816572B1 (en)
CN (2) CN1308347C (en)
AT (1) ATE269357T1 (en)
AU (1) AU763954B2 (en)
BR (1) BR0010017A (en)
CA (1) CA2372053C (en)
DE (1) DE60011612T2 (en)
ES (1) ES2223705T3 (en)
HK (1) HK1045700B (en)
IL (1) IL145941A (en)
MX (1) MXPA01010891A (en)
NZ (1) NZ514918A (en)
WO (1) WO2000064946A2 (en)
ZA (2) ZA200108612B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7204132B2 (en) 2017-05-02 2023-01-16 国立研究開発法人国立がん研究センター Conjugates of plasmin-cleavable anti-insoluble fibrin antibodies and drugs
US11964021B2 (en) 2021-03-25 2024-04-23 Engenelc Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Families Citing this family (520)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
EP1060242A4 (en) * 1998-01-23 2003-09-17 Imclone Systems Inc Purified populations of stem cells
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
EP1086223B1 (en) * 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
EP1117762A4 (en) * 1998-09-29 2004-02-25 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
CN1330555A (en) * 1998-12-21 2002-01-09 路德维格癌症研究所 Antibodies to truncated VEGF-D and uses thereof
IT1312077B1 (en) * 1999-04-15 2002-04-04 Univ Degli Studi Milano ANTIANGIOGENIC ACTIVITY POLYPEPTIDES.
US6524583B1 (en) * 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2003511355A (en) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト Endothelin signaling pathway inhibitors and αvβ3 receptor antagonists for combination therapy
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2001058240A2 (en) * 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
CA2400622A1 (en) * 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072829A2 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
FR2813606B1 (en) * 2000-09-01 2004-04-30 Inst Nat Sante Rech Med TRUNKED PROTEIN BARD1, AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
US8314060B2 (en) * 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
IL154696A (en) * 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
CA2421783A1 (en) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft Receptor in the edb fibronectin domain
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
TWI304061B (en) * 2000-10-20 2008-12-11 Eisai R&D Man Co Ltd Nitrogen-containing aromatic ring derivatives
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US7319139B2 (en) * 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EA007388B1 (en) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Modified antibodies and methods of use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
EP1379274A4 (en) * 2001-03-23 2006-02-15 Univ Texas Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
US20040198960A1 (en) * 2001-03-29 2004-10-07 Janoff Edward N Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
JP2004536579A (en) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Vascular endothelial growth factor 2
AU2002256172A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20030007974A1 (en) * 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
MXPA03010804A (en) * 2001-06-01 2004-11-22 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof.
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
AU2002312410A1 (en) * 2001-06-08 2002-12-23 Target Protein Technologies, Inc. Tissue-specific endothelial membrane proteins
EP1515707A4 (en) * 2001-06-20 2005-10-19 Imclone Systems Inc Method of treating atherosclerosis and other inflammatory diseases
WO2002102972A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
ATE477280T1 (en) * 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2453474A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
DE60223556T2 (en) * 2001-08-10 2008-09-18 Imclone Systems, Inc. MEDICAL USE OF STEM CELLS EXPRESSING VEGFR-1
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (en) * 2001-09-06 2015-06-02 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
US7192586B2 (en) * 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
US20030148409A1 (en) * 2001-10-15 2003-08-07 Edmund Rossi Direct targeting binding proteins
IL161268A0 (en) * 2001-11-07 2004-09-27 Agensys Inc Nucleic acid and corresponding protein entitled 161p2f10b and pharmaceutical and diagnostic compositions containing the same
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002365603A1 (en) * 2001-12-04 2003-06-17 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
EP1467757B1 (en) * 2001-12-28 2008-05-07 Amgen Fremont Inc. Use of antibodies against the muc18 antigen
EP1467756A4 (en) * 2001-12-28 2007-03-21 Abgenix Inc Methods for using anti-muc18 antibodies
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
NZ533933A (en) * 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
IL162201A0 (en) * 2002-01-03 2005-11-20 Schering Ag New methods for diagnosis and treatment of tumours
JP4242590B2 (en) * 2002-01-11 2009-03-25 俊一 塩澤 Disease susceptibility genes for rheumatoid arthritis and use thereof
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
AU2002364051A1 (en) * 2002-01-24 2003-09-02 Children's Medical Center Corporation Anti-cancer combination and use thereof
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7071311B2 (en) * 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
JP2005533486A (en) * 2002-02-20 2005-11-10 ダイアックス、コープ MHC-peptide complex binding ligand
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK1487856T3 (en) * 2002-03-04 2010-10-18 Imclone Llc KDR-specific human antibodies and their use
SG108837A1 (en) * 2002-03-11 2005-02-28 Pi Eta Consulting Co Pte Ltd An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
AU2003276825A1 (en) * 2002-03-15 2004-01-23 The Regents Of The University Of California Method of immunotherapy
EP1575525A4 (en) * 2002-03-15 2008-04-02 Attenuon Llc Cell surface tropomyosin as a target of angiogenesis inhibition
US20070178065A1 (en) * 2002-05-03 2007-08-02 Lattime Edmund C Neutralizing factors as vaccine adjuvants
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
EA008770B1 (en) * 2002-05-15 2007-08-31 Янссен Фамацевтика Н.В. N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
EP1507562B1 (en) * 2002-05-29 2010-03-24 Immunomedics, Inc. Compositions for radioimmunotherapy of brain
JP4511108B2 (en) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド Human prolactin antagonist-angiogenesis inhibitor fusion protein
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
CA2489467C (en) * 2002-06-14 2015-02-24 Immunomedics, Inc. Humanized monoclonal antibody hpam4
WO2003106497A1 (en) * 2002-06-14 2003-12-24 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
US9599619B2 (en) 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US8821868B2 (en) 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
SI1517921T1 (en) * 2002-06-28 2006-10-31 Domantis Ltd Dual specific ligands with increased serum half-life
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CN104001181B (en) 2002-07-15 2017-05-10 得克萨斯大学体系董事会 Selected antibody binding to anionic phospholipids and amino phosphatidic and treating and diagnosing application thereof
ES2392426T3 (en) 2002-07-18 2012-12-10 Janssen Pharmaceutica Nv Kinase inhibitors with substituted triazine
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
ATE516818T1 (en) 2002-07-31 2011-08-15 Seattle Genetics Inc AURISTATIN CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
WO2004020435A1 (en) * 2002-08-16 2004-03-11 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
KR20050057631A (en) * 2002-10-10 2005-06-16 메르크 파텐트 게엠베하 Bispecific anti-erb-b antibodies and their use in tumor therapy
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
PT1572748E (en) * 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20060039858A1 (en) * 2003-02-11 2006-02-23 Ekaterina Dadachova Radiolabeled antibodies and peptides for treatment of tumors
US7402385B2 (en) * 2003-02-11 2008-07-22 Albert Einstein College Of Medicine Of Yeshiva University Radiolabeled antibodies for treatment of tumors
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004073656A2 (en) * 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7759468B1 (en) * 2003-03-05 2010-07-20 University Of Kentucky Research Foundation Bioactive peptide-based probes
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DE602004023183D1 (en) * 2003-03-07 2009-10-29 Univ Texas PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES
US7994159B2 (en) * 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
WO2004087206A2 (en) * 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05012613A (en) * 2003-05-23 2006-05-25 Genentech Inc Compositions and methods for the diagnosis and treatment of tumors of glial origin.
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
UA101945C2 (en) * 2003-05-30 2013-05-27 Дженентек, Инк. Treatment of cancer using bevacizumab
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2005000223A2 (en) * 2003-06-04 2005-01-06 Children's Medical Center Corporation Method of treating retinopathies and disorders associated with blood vessel loss
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
ATE546153T1 (en) 2003-06-17 2012-03-15 Mannkind Corp COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS FOR THE TREATMENT OF DIFFERENT TYPES OF CANCER
NZ543495A (en) 2003-06-25 2009-04-30 Peregrine Pharmaceuticals Inc Method and apparatus for continuous large-scale radiolabeling of proteins
AU2004260936B2 (en) * 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CN1816351A (en) * 2003-06-27 2006-08-09 艾伯吉尼斯公司 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
RU2376315C2 (en) 2003-07-02 2009-12-20 Ново Нордиск А/С Composition and method for control of activity of natural killer cells
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
CA2533878A1 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AU2012201667B2 (en) * 2003-08-01 2014-11-27 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AP2012006644A0 (en) * 2003-08-01 2012-12-31 Genentech Inc Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
EP1651663B1 (en) * 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US7547518B2 (en) * 2003-08-19 2009-06-16 Becton, Dickinson And Company Method of screening endothelial cells for angiogenic capability
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
JP4303726B2 (en) * 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Urea derivative and method for producing the same
WO2005047319A2 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin
CN1914179A (en) * 2003-11-13 2007-02-14 詹森药业有限公司 Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
WO2005048938A2 (en) * 2003-11-13 2005-06-02 California Pacific Medical Center Anti-pecam therapy for metastasis suppression
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
RU2402567C2 (en) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Inhibitors of receptors of type 2 vessel endothelium growth factor
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
US7939634B2 (en) * 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
AU2005219413A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
EP1729750A2 (en) * 2004-03-02 2006-12-13 The Ludwig Institute for Cancer Research Method for inhibiting tumor formation and growth
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
DE602005027673D1 (en) * 2004-03-05 2011-06-09 Vegenics Pty Ltd MATERIALS AND METHODS FOR GROWTH FACTORY BONDING CONSTRUCTS
EP1723422A2 (en) * 2004-03-05 2006-11-22 The Scripps Research Institute High throughput glycan microarrays
WO2005087811A2 (en) * 2004-03-10 2005-09-22 Creighton University Estrogen receptors and methods of use
AU2012265582B2 (en) * 2004-03-26 2015-04-16 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US8470315B2 (en) * 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
BRPI0418766B8 (en) * 2004-04-22 2021-05-25 Agensys Inc antibody or fragment thereof, vector, pharmaceutical composition, assay and method for detecting the presence of step-1 protein, as well as a method for delivering a cytotoxic agent or a diagnostic agent
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
CN1304427C (en) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 Angiogenesis inhibiting fusion protein and its use
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8029766B2 (en) * 2004-06-18 2011-10-04 Elmaleh David R Intravascular imaging device and uses thereof
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
SI2287195T1 (en) 2004-07-01 2019-08-30 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
JP4991532B2 (en) * 2004-07-02 2012-08-01 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Alpha helix mimic
US7943294B2 (en) 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
MX2007001241A (en) * 2004-07-30 2007-07-11 Regeneron Pharma Methods of treating type i diabetes by blocking vegf-mediated activity.
ES2381557T3 (en) 2004-08-03 2012-05-29 Innate Pharma Therapeutic and diagnostic methods and compositions to determine 4IG-B7-H3 and its homologous receptor in NK cells
US20070003943A1 (en) * 2004-08-09 2007-01-04 Northwestern University Tumor angiogenesis inhibitor alpha 1-antitrypsin
CN1316249C (en) * 2004-08-25 2007-05-16 北京健平九星生物医药科技有限公司 Enzyme-linked assay kit and producing process thereof
ES2425750T3 (en) * 2004-08-31 2013-10-17 Newsouth Innovations Pty Limited VEGF inhibition
PE20060817A1 (en) * 2004-09-10 2006-10-10 Wyeth Corp HUMANIZED AND CONJUGATED ANTI-5T4 ANTIBODIES ANTI-5T4 / CALICHEAMICIN ANTIBODIES
WO2006030947A1 (en) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
EP1812033A4 (en) * 2004-10-06 2009-11-11 Tiltan Pharma Ltd Method and composition for enhancing anti-angiogenic therapy
US7491390B2 (en) * 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
RS52539B (en) * 2004-10-21 2013-04-30 Genentech Inc. Method for treating intraocular neovascular diseases
ES2325344B1 (en) * 2004-11-02 2010-06-09 Univ Madrid Autonoma MULTIFUNCTIONAL AND MULTIVALENT ANGIOGENESIS INHIBITORS.
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
PT1819358E (en) * 2004-11-18 2014-11-17 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
PT1838733E (en) 2004-12-21 2011-12-13 Medimmune Ltd Antibodies directed to angiopoietin-2 and uses thereof
EP1842557B1 (en) 2004-12-22 2013-10-23 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
NO346624B1 (en) 2004-12-28 2022-11-07 Univ Di Genova Monoclonal antibody against NKG2A
MX2007008013A (en) * 2004-12-29 2008-02-07 Mannkind Corp Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006072626A1 (en) * 2005-01-06 2006-07-13 Novo Nordisk A/S Kir-binding agents and methods of use thereof
US8551483B2 (en) 2005-01-06 2013-10-08 Innate Pharma S.A.S. Methods of treating viral infections by administering KIR2DL-binding antibodies
JP5855326B2 (en) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス Anti-KIR combination therapy and method
WO2006084054A2 (en) * 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
WO2006082428A2 (en) 2005-02-03 2006-08-10 Topotarget Uk Limited Combination therapies using hdac inhibitors
EP2404937A1 (en) 2005-02-07 2012-01-11 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
AU2006218653A1 (en) * 2005-03-02 2006-09-08 Barnett, Gene Ph.D. Pharmaceutically acceptable carrier for ophthalmic compositions
US7351411B2 (en) * 2005-03-11 2008-04-01 Regeneron Pharmaceuticals, Inc. Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
EP3195874A1 (en) 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
AU2006230563B8 (en) * 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US8350009B2 (en) * 2005-03-31 2013-01-08 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
ES2477765T3 (en) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Binding agents to humanized anti-cd70 and their uses
EP2494969B1 (en) 2005-05-13 2015-03-25 TopoTarget UK Limited Pharmaceutical formulations of HDAC inhibitors
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5416968B2 (en) 2005-06-17 2014-02-12 マンカインド コーポレイション Methods and compositions for eliciting a multivalent immune response against dominant and subdominant epitopes expressed on cancer cells and tumor stroma
EP1748050A1 (en) * 2005-07-28 2007-01-31 Rijksuniversiteit Groningen Targeting-enhanced activation of galectins
JP5066446B2 (en) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Method for assay on the effect of vascularization inhibitor
ATE502956T1 (en) 2005-08-15 2011-04-15 Vegenics Pty Ltd MODIFIED VEGF AND PDGF WITH IMPROVED ANGIOGENIC PROPERTIES
WO2007026864A1 (en) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegradability
US8044179B2 (en) * 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US8124738B2 (en) * 2005-09-26 2012-02-28 Medarex, Inc. Human monoclonal antibodies to CD70
US20070071756A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
CN101300272B (en) 2005-10-14 2013-09-18 依奈特制药公司 Compositions and methods for treating proliferative disorders
CN101340909B (en) 2005-10-18 2012-01-11 詹森药业有限公司 Method of inhibiting flt3 kinase
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
JP2009516757A (en) * 2005-10-21 2009-04-23 メディバス エルエルシー Poly (ester urea) polymers and methods of use
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20110125203A1 (en) * 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
US7747324B2 (en) * 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US7725188B2 (en) * 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US8041428B2 (en) * 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8812112B2 (en) * 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20090155283A1 (en) * 2005-12-01 2009-06-18 Drew Philip D Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
PT1962895E (en) † 2005-12-16 2013-03-28 Regeneron Pharma Therapeutic use of a dll4 antagonist and a vegf inhibitor for inhibiting tumor growth
ME02736B (en) * 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
CA2634783A1 (en) * 2005-12-23 2008-05-08 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
US20090317475A1 (en) * 2006-01-03 2009-12-24 Beardsley Robert A Combination antitumor therapies
AU2007246776B2 (en) * 2006-01-23 2012-02-16 Ad Group Systems and methods for distributing emergency messages
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
CN101400403A (en) * 2006-02-10 2009-04-01 电子核心公司 Methods and apparatus for treating anaphylaxis using electrical modulation
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TWI390034B (en) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US20100241188A1 (en) * 2009-03-20 2010-09-23 Electrocore, Inc. Percutaneous Electrical Treatment Of Tissue
MX2008013530A (en) 2006-04-20 2009-01-14 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase.
ES2389678T3 (en) 2006-04-20 2012-10-30 Janssen Pharmaceutica Nv A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumors or mastocytosis
DK2021335T3 (en) * 2006-04-20 2011-09-05 Janssen Pharmaceutica Nv Heterocyclic compounds as C-FMS kinase inhibitors
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
CA2651194A1 (en) * 2006-05-04 2007-11-15 Fondation Ophthalmologique Aldolphe De Rothschild Methods for treating neovascular diseases
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
CN101443009A (en) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
EA200870555A1 (en) * 2006-05-19 2009-04-28 Тева Фармасьютикал Индастриз, Лтд. SLIP PROTEINS, THEIR APPLICATION AND METHODS OF THEIR PRODUCTION
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2007144893A2 (en) * 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2040751A2 (en) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
KR101406811B1 (en) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 Vegf antagonist formulations suitable for intravitreal administration
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
US20100021379A1 (en) * 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
KR101137454B1 (en) * 2006-07-28 2012-04-20 사노피 Composition and method for treatment of tumors
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
WO2008026748A1 (en) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
ME02371B (en) * 2006-09-29 2016-06-20 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
MX2009004070A (en) * 2006-10-17 2009-04-27 Dyax Corp Sequential combination therapy.
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
WO2008047925A1 (en) * 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2008055072A2 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
MX2009004532A (en) * 2006-10-27 2009-09-04 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate.
PT2502938E (en) 2006-10-27 2015-06-05 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp Autoimmune disease biomarkers
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
KR20090088946A (en) * 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 Human antibodies that bind cd70 and uses thereof
TW200831538A (en) * 2006-12-19 2008-08-01 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
US20100111851A1 (en) * 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
AU2008211952B2 (en) * 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US7816390B2 (en) * 2007-01-31 2010-10-19 Janssen Pharmaceutica Nv N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
US9073997B2 (en) * 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20080286337A1 (en) * 2007-05-15 2008-11-20 Boston Foundation For Sight Method of treating a disease in an eye using a scleral lens
AU2008259513B2 (en) * 2007-06-06 2014-07-24 Domantis Limited Polypeptides, antibody variable domains and antagonists
KR100883430B1 (en) * 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
PE20090368A1 (en) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
WO2008155378A1 (en) * 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US8334239B2 (en) 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (en) 2007-07-16 2014-07-02 健泰科生物技术公司 Humanized anti-CD79b antibodies and immunoconjugates and methods of use
WO2009025806A2 (en) * 2007-08-20 2009-02-26 Adnexus, A Bristol-Myers Squibb R & D Company Use of vegfr-2 inhibitors for treating metastatic cancer
EP3492488A1 (en) * 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
WO2009040517A2 (en) * 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
JO3240B1 (en) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US20110003890A1 (en) * 2007-11-08 2011-01-06 Jason Joel Schwartz Use of angiogenesis antagonists in conditions of abnormal venous proliferation
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
DK2219672T3 (en) 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
AU2013205269B2 (en) * 2007-11-09 2016-05-19 Affitech Research As Anti-VEGF antibody compositions and methods
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US20110112291A1 (en) * 2007-11-30 2011-05-12 Eva Hoess Stabilization of conjugates comprising a thiourea linker
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
BRPI0821600A2 (en) * 2007-12-28 2015-06-23 Bioinvent Int Ab Pharmaceutical composition, article of manufacture, kit of parts, method of combating atherosclerosis, or atherosclerosis-associated cardiovascular disease, and use of an antibody
CA2713137C (en) * 2008-01-25 2017-10-24 Hadasit Medical Research Services And Development Ltd. Targeting of innate immune response to tumor site
JP5399926B2 (en) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of vascular inhibitor and taxane
MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
KR20100128291A (en) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Targeted therapeutics based on engineered proteins that bind egfr
CN102083428A (en) * 2008-03-07 2011-06-01 顶标公司 Methods of treatment employing prolonged continuous infusion of Belinostat
ES2629405T3 (en) 2008-03-18 2017-08-09 Genentech, Inc. Combinations of a drug-antibody anti-HER2 and docetaxel conjugate
CA2719400C (en) * 2008-03-26 2017-11-14 Epitomics, Inc. Anti-vegf antibody
AU2014202474B2 (en) * 2008-03-26 2016-07-28 Epitomics, Inc. Anti-VEGF antibody
KR100998569B1 (en) * 2008-03-31 2010-12-07 한국원자력연구원 A radioimmunoconjugate for diagnosis and treatment of cancer or metastasis and development of cancer or cancer metastasis inhibitor using thereof
WO2009125394A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
EP2636513B1 (en) * 2008-04-10 2014-08-27 Stratasys Ltd. System and method for three dimensional model printing
EP2383292A1 (en) 2008-05-02 2011-11-02 Novartis AG Improved fibronectin-based binding molecules and uses thereof
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
ES2338400B1 (en) * 2008-05-06 2011-09-14 David Benet Ferrus SET OF ANTIANGIOGEN MOLECULES AND ITS USE.
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
JP2011520961A (en) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Scaffold domain protein based on multivalent fibronectin
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
KR101671886B1 (en) 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Stable and soluble antibodies inhibiting vegf
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
AU2011207189B2 (en) * 2008-08-08 2014-01-16 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
JP2012504423A (en) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド Therapeutic ribonuclease
CA2739757C (en) * 2008-10-07 2016-07-05 Rexahn Pharmaceuticals, Inc. Hpma - docetaxel or gemcitabine conjugates and uses therefore
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
MX2011000455A (en) 2008-11-07 2011-02-25 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2.
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli C-MET ANTIBODIES
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
KR101093717B1 (en) 2008-11-26 2011-12-19 한국생명공학연구원 VEGF?specific human antibody
AU2009324296B2 (en) 2008-12-12 2016-07-28 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
BRPI1006141B8 (en) * 2009-01-12 2021-05-25 Cytomx Therapeutics Llc modified antibody compositions, methods of making and using the same
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP2393513B1 (en) * 2009-02-06 2016-10-19 The General Hospital Corporation Methods of treating vascular lesions
EP2396036B1 (en) 2009-02-13 2017-06-28 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
ES2712732T3 (en) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Methods and kits for the diagnosis of cancer and the prediction of therapeutic value
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
KR101224468B1 (en) * 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
US20120135064A1 (en) * 2009-05-27 2012-05-31 Northeastern University Conjugated nanodelivery vehicles
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
PL2451279T3 (en) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
CN102002104A (en) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 Anti-VEGF monoclonal antibody and medicinal composition containing same
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
US8642515B2 (en) 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
EP2293071A1 (en) 2009-09-07 2011-03-09 Universität Zu Köln Biomarker for colorectal cancer
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CN104587484A (en) 2009-10-13 2015-05-06 瑞沙恩医药公司 Polymeric systems for the delivery of anticancer drugs
JP5965318B2 (en) 2009-10-16 2016-08-03 オンコメッド ファーマシューティカルズ インコーポレイテッド Therapeutic combinations of DLL4 antagonists and antihypertensive agents and methods of treatment therewith
CA2776513C (en) 2009-11-24 2017-08-01 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
MX354143B (en) 2009-12-02 2018-02-14 Imaginab Inc J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use.
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
AU2011213609B2 (en) * 2010-02-08 2016-11-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2566973A4 (en) 2010-05-04 2013-11-27 Medimmune Llc Optimized degenerative muscle disease diagnostics and treatments
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
ES2573515T3 (en) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Anti-tumor agent that uses compounds with combined kinase inhibitory effect
CN103119063B8 (en) * 2010-07-07 2016-10-12 土耳其科学技术研究理事会 It is bound to VEGF 2(VEGFR-2/KDR) upper and block the recombinant antibodies structure of its activity
CN101942022B (en) * 2010-07-29 2013-07-24 华东理工大学 Anti-human epidermal growth factor receptor single-chain antibody-ferritin heavy chain subunit protein and construction method and application thereof
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CA2827076A1 (en) 2011-02-15 2012-08-23 Immumomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
EP2697394A4 (en) 2011-04-12 2015-01-14 Electronic Biosciences Inc Site specific chemically modified nanopore devices
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
EP2726612B1 (en) 2011-06-30 2019-03-06 Gene Signal International SA Composition comprising inhibitors of irs-1 and of vegf
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
CN102492038B (en) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
HUE052136T2 (en) * 2011-12-13 2021-04-28 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
SG11201404608WA (en) 2012-02-13 2014-09-26 Gamida Cell Ltd Mesenchymal stem cells conditioned medium and methods of generating and using the same
JP2015512877A (en) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド Combination of clusterin inhibitor and EGFR inhibitor for the treatment of cancer
JP2015511012A (en) 2012-03-06 2015-04-13 ライフ テクノロジーズ コーポレーション Biomarkers for systemic lupus erythematosus
CA2868883C (en) 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US20150204873A1 (en) 2012-06-18 2015-07-23 Electonic Biosciences, Inc. Cell-free assay device and methods of use
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
KR102356017B1 (en) 2012-12-13 2022-01-27 이뮤노메딕스, 인코오포레이티드 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
AU2014205369B2 (en) 2013-01-11 2018-08-09 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
RS60026B1 (en) 2013-02-18 2020-04-30 Vegenics Pty Ltd Ligand binding molecules and uses thereof
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR102049990B1 (en) 2013-03-28 2019-12-03 삼성전자주식회사 Fusion protein comprising anti-c-Met antibody and VEGF binding fragment
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
CN105264380B (en) 2013-05-14 2017-09-05 卫材R&D管理有限公司 Pleasure is cut down for the biological marker of Buddhist nun's compound response for predicting and evaluating carcinoma of endometrium subject
KR101541478B1 (en) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 Anti-vegf antibodies and pharmaceutical composition comprising same for preventing, diagnosing or treating cancer or angiogenesis-related disease
CN110193009A (en) 2013-07-12 2019-09-03 伊维希比奥公司 Method for treating or preventing ophthalmology disease
ME03476B (en) 2013-08-01 2020-01-20 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN113151180A (en) * 2013-12-02 2021-07-23 菲奥医药公司 Immunotherapy of cancer
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
CN106132436B (en) 2014-02-21 2021-06-15 Ibc药品公司 Disease therapy by inducing an immune response to TROP-2 expressing cells
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
ES2960619T3 (en) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Loaded Linkers and Their Uses for Conjugation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
WO2015164541A1 (en) * 2014-04-22 2015-10-29 Presage Biosciences, Inc. Methods and devices for evaluating drug candidates
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6685276B2 (en) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ Method for predicting outcome of treatment with aflibercept in patients suspected of having cancer
HRP20221047T1 (en) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
LT3262071T (en) 2014-09-23 2020-06-25 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
EP3954373A1 (en) 2014-10-07 2022-02-16 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
TWI695837B (en) 2014-12-04 2020-06-11 比利時商健生藥品公司 A triazolopyridazine as a kinase modulator
ES2833530T3 (en) * 2015-01-06 2021-06-15 Zhuhai Essex Bio Pharmaceutical Co Ltd Anti-VEGF antibody
AR103477A1 (en) 2015-01-28 2017-05-10 Lilly Co Eli VEGFA / ANG2 COMPOUNDS
JP6792546B2 (en) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to suppress bitterness of quinoline derivatives
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CN107801379B (en) 2015-06-16 2021-05-25 卫材R&D管理有限公司 Anticancer agent
CA2983597A1 (en) 2015-06-25 2016-12-29 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
JP6893504B2 (en) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Serum albumin-binding fibronectin type III domain with fast dissociation rate
CN116987187A (en) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 Optimized variants of anti-VEGF antibodies
AU2016343860A1 (en) * 2015-10-30 2018-05-10 The Jackson Laboratory Compositions and methods relating to tumor analysis
WO2017091580A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
KR102261636B1 (en) 2015-12-03 2021-06-07 리제너론 파마슈티칼스 인코포레이티드 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017119434A1 (en) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Antibody inhibiting binding between vegf and nrp1
CN108699141B (en) 2016-01-06 2022-06-17 定制药品研究株式会社 High affinity anti-VEGF antibodies
KR20230124093A (en) * 2016-05-10 2023-08-24 제넨테크, 인크. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
AU2017275081B2 (en) * 2016-05-30 2023-12-07 Eiken Kagaku Kabushiki Kaisha Anti-human hemoglobin monoclonal antibody or antibody kit, insoluble carrier particle to which anti-human hemoglobin monoclonal antibody is immobilized, and measurement reagent and measurement method using same
GB2551979A (en) 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates
CN115028728A (en) * 2016-09-27 2022-09-09 高地和群岛大学 Antigen biomarkers
CN109789209A (en) * 2016-10-14 2019-05-21 诺华股份有限公司 Use the method for CSF-1R inhibitors to treat ocular diseases
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102459468B1 (en) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
GB2556055B (en) 2016-11-16 2022-03-23 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
ES2955852T3 (en) 2017-04-03 2023-12-07 Hoffmann La Roche STEAP-1 binding antibodies
CN110621336A (en) 2017-05-16 2019-12-27 戊瑞治疗有限公司 Combination of an anti-FGFR 2 antibody with a chemotherapeutic agent in the treatment of cancer
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
JP7436365B2 (en) 2017-12-29 2024-02-21 エフ． ホフマン－ラ ロシュ アーゲー Anti-VEGF antibodies and methods of use
KR102644938B1 (en) * 2018-03-19 2024-03-07 주식회사 파멥신 Anti-vegfr-2 antibody
BR112020022294A2 (en) 2018-05-04 2021-02-23 Tollys composition and use of a composition
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
JP2022545181A (en) 2019-08-30 2022-10-26 ユニバーシティ オブ ロチェスター Septin inhibitors for cancer therapy
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022239720A1 (en) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 Antibody having reduced binding affinity for antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855866A (en) * 1992-03-05 1999-01-05 Board Of Regenis, The University Of Texas System Methods for treating the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
FR2566271B1 (en) 1984-06-20 1986-11-07 Sanofi Sa NOVEL CYTOTOXIC CONJUGATES FOR USE IN THERAPEUTICS AND PROCESS FOR OBTAINING SAME
CA1289880C (en) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
FR2601679B1 (en) 1986-07-15 1990-05-25 Sanofi Sa IMMUNOTOXINS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5008196A (en) 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5024834A (en) 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US6007817A (en) 1988-10-11 1999-12-28 University Of Southern California Vasopermeability enhancing immunoconjugates
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1992014748A1 (en) 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US5234955A (en) 1991-12-20 1993-08-10 Eli Lilly And Company Antitumor compositions and methods of treatment
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5281700A (en) 1992-08-11 1994-01-25 The Regents Of The University Of California Method of recovering endothelial membrane from tissue and applications thereof
ATE348110T1 (en) 1992-10-28 2007-01-15 Genentech Inc HVEGF RECEPTOR AS A VEGF ANTAGONIST
CA2148244A1 (en) 1992-10-29 1994-05-11 Christopher Richard Parish Angiogenesis inhibitory antibodies
CN1173991C (en) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 Fik-1 as receiptor of growth factor of blood vessel inner-skin
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
AU702250B2 (en) 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
JPH09124697A (en) 1995-11-01 1997-05-13 Toagosei Co Ltd Peptide and monoclonal antibody
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6008319A (en) 1996-12-23 1999-12-28 University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
US6291667B1 (en) 1997-01-31 2001-09-18 Parkash S. Gill Method and composition for treatment of kaposi's sarcoma
KR100794454B1 (en) 1997-04-07 2008-01-16 제넨테크, 인크. Anti-VEGF Antibodies
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69832798T2 (en) * 1997-06-03 2006-09-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. REGULATORY SEQUENCES FOR THE IN VIVO EXPRESSION OF A HETEROLOGICAL DNA SEQUENCE IN ENDOTHELIAL CELLS AND THEIR USES.
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
ATE300957T1 (en) 1998-12-22 2005-08-15 Genentech Inc ANTAGONISTS OF VASCULAR-ENDOTHELIAL CELL GROWTH FACTORS AND THEIR APPLICATION
US6524583B1 (en) 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855866A (en) * 1992-03-05 1999-01-05 Board Of Regenis, The University Of Texas System Methods for treating the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BREKKEN ROLF A ET AL: "Vascular endothelial growth factor as a marker of tumor endothelium.", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1952 - 1959, XP000918910, ISSN: 0008-5472 *
DEONARAIN M P ET AL: "Targeting enzymes for cancer therapy: Old enzymes in new roles.", BRITISH JOURNAL OF CANCER, vol. 70, no. 5, 1994, pages 786 - 794, XP000654784, ISSN: 0007-0920 *
GIORGIO NICK A ET AL: "Ellipticine conjugated to anti VEGFR2 monoclonal antibodies as reagents for targeting angiogenesis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 387, XP000918901, ISSN: 0197-016X *
HAISMA H J ET AL: "ANALYSIS OF A CONJUGATE BETWEEN ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY AND ALKALINE PHOSPHATASE FOR SPECIFIC ACTIVATION OF THE PRODRUG ETOPOSIDE PHOSPHATE", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 34, no. 5, 1992, pages 343 - 348, XP000918911, ISSN: 0340-7004 *
HUBER J ET AL: "Vascular endothelial growth factor receptor (VEGFR-2) antibody therapy combined with conventional chemotherapy inhibits growth of established tumors in mice.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 567, XP000918903, ISSN: 0197-016X *
MULLER YVES A ET AL: "Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 14, 1997, 1997, pages 7192 - 7197, XP000918906, ISSN: 0027-8424 *
ORTEGA NATHALIE ET AL: "Signal relays in the VEGF system.", FRONTIERS IN BIOSCIENCE, vol. 4, 1 February 1999 (1999-02-01), pages D141 - 152, XP000940560 *
WITTE LARRY ET AL: "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.", CANCER AND METASTASIS REVIEWS, vol. 17, no. 2, June 1998 (1998-06-01), pages 155 - 161, XP000940443, ISSN: 0167-7659 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7204132B2 (en) 2017-05-02 2023-01-16 国立研究開発法人国立がん研究センター Conjugates of plasmin-cleavable anti-insoluble fibrin antibodies and drugs
US11964021B2 (en) 2021-03-25 2024-04-23 Engenelc Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Also Published As

Publication number Publication date
CN1308347C (en) 2007-04-04
US6887468B1 (en) 2005-05-03
KR100816572B1 (en) 2008-03-24
KR20020019905A (en) 2002-03-13
IL145941A0 (en) 2002-07-25
BR0010017A (en) 2002-06-11
WO2000064946A2 (en) 2000-11-02
DE60011612D1 (en) 2004-07-22
HK1045700A1 (en) 2002-12-06
CA2372053C (en) 2008-09-02
US6676941B2 (en) 2004-01-13
ATE269357T1 (en) 2004-07-15
US6342219B1 (en) 2002-01-29
US7056509B2 (en) 2006-06-06
US6416758B1 (en) 2002-07-09
ZA200108285B (en) 2002-08-28
HK1045700B (en) 2007-07-27
AU763954B2 (en) 2003-08-07
ES2223705T3 (en) 2005-03-01
AU4804900A (en) 2000-11-10
JP2011046720A (en) 2011-03-10
US20020119153A1 (en) 2002-08-29
EP1185559A2 (en) 2002-03-13
CN101073668A (en) 2007-11-21
US20030175276A1 (en) 2003-09-18
JP4926320B2 (en) 2012-05-09
ZA200108612B (en) 2002-06-07
EP1179541A1 (en) 2002-02-13
US6524583B1 (en) 2003-02-25
DE60011612T2 (en) 2005-07-07
EP1179541B1 (en) 2004-06-16
CA2372053A1 (en) 2000-11-02
IL145941A (en) 2007-08-19
JP2002543093A (en) 2002-12-17
NZ514918A (en) 2003-11-28
MXPA01010891A (en) 2002-11-07
CN1358197A (en) 2002-07-10
US6342221B1 (en) 2002-01-29

Similar Documents

Publication Publication Date Title
WO2000064946A3 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
MX2010005104A (en) Anti-vegf antibody compositions and methods.
MY151191A (en) Novel antibodies
PT1187918E (en) TEK ANTAGONISTS
WO1999063930A3 (en) Novel angiotensin receptor modulators and their uses
WO2011025964A3 (en) Therapeutic dll4 binding proteins
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2006015060A3 (en) Isoindoline compounds and methods of their use
MY159375A (en) Combinatorial therapy
HK1075256A1 (en) Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
WO2001060806A3 (en) Substituted arylpyrazines
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
PL2097453T3 (en) Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii)
WO2007025303A3 (en) Non-steroidal antiandrogens
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2002020768A3 (en) Caveolin peptides and their use as therapeutics
WO2002077172A3 (en) Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
WO2009015908A3 (en) Anti ephb4 antibodies and antibody fragments
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006083562A3 (en) Method and multicomponent conjugates for treating cancer
DK1079851T3 (en) Use of anti-prolactin agents for the treatment of cancer
WO2002022166A3 (en) Tweak receptor agonists as anti-angiogenic agents
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
WO1999064050A8 (en) Novel potassium channel drugs and their uses
WO2002043776A3 (en) Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809417.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/08612

Country of ref document: ZA

Ref document number: 200108612

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 48049/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 514918

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2372053

Country of ref document: CA

Ref document number: 2372053

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 614295

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017013746

Country of ref document: KR

Ref document number: PA/a/2001/010891

Country of ref document: MX

Ref document number: 2000930183

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017013746

Country of ref document: KR

Ref document number: 2000930183

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 48049/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000930183

Country of ref document: EP